#AI #Canada #Toronto #oncology #Xtalks

Upcoming Webinar on Advancements in Oncology

In the ever-evolving field of oncology research, the integration of advanced technologies is becoming increasingly essential for successful drug development. One such promising approach is the use of integrated multi-omics data combined with cutting-edge AI tools. Xtalks is hosting a free webinar titled Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, which aims to explore these topics in depth.

Webinar Details

Set to take place on September 3, 2025, at 11 AM EDT, this enlightening session will feature Dr. Michael Ritchie, Chief Commercial Officer at Champions Oncology. Participants will gain insights into the methodologies that can de-risk early-stage drug development for oncology programs and learn how to harness multi-omics data to enhance translational confidence.

The Importance of Multi-Omics in Oncology

In the context of drug development, multi-omics refers to the comprehensive approach that integrates various biological data types such as genomics, proteomics, and metabolomics. Often, the existing datasets available for oncology research are fragmented, lacking the necessary integration and depth, which poses significant challenges. This webinar presents a case-driven approach to demonstrate how a deeply profiled, functionalized tumor dataset can lead to novel oncology target discovery.

Case Study Insights

One of the highlights will be a case study discussing the discovery of the VPS4A/B protein associated with vacuolar protein sorting. This undertaking involved a gene knockdown screen conducted on patient-derived xenograft tumors grown in 3D ex vivo cultures. Machine learning models trained on integrated data sources accurately predicted VPS4 sensitivity, which is a pivotal step in identifying effective cancer treatments.

The outcome led to the innovation of CHAMP-002, a chemotype inducing strong immunogenic responses and showing efficacy across multiple tumor types, ideally combined with PD-1 blockade therapies. Such real-world applications of functional multi-omic data showcase its potential to drive effective translational research.

What Participants Will Learn

Attendees will walk away with actionable strategies to integrate multi-omic approaches and AI into their own R&D pipelines. The key focus areas include:

• - Structured Data Integration: Learning how to create AI/ML-ready datasets that are structured, exportable, and directly relevant to tumor biology.
• - Multimodal Data Utilization: Understanding how to layer clinical history, drug response data, omics, and phenotypic data cohesively.
• - Translational Strategies: Developing a framework that aligns internal decision-making, target selection, biomarker validation, and early development strategies based on real-world implications rather than abstract models.

As the landscape of cancer research grows increasingly complex, this webinar offers a crucial opportunity for pharma R&D leaders to bridge the gap between available data and clinical applications. Those struggling with limitations in public datasets or those who have found it challenging to replicate internal models are especially encouraged to participate.

Register Now

To join Dr. Ritchie and gain valuable insights into the integration of functionalized tumor data and AI in oncology, register for the webinar today. This session not only addresses the current challenges in drug target discovery but also aims to inspire innovative approaches for overcoming these hurdles.

Xtalks, recognized as a foremost provider of educational webinars, remains committed to delivering essential knowledge to professionals in the life sciences and healthcare sectors.

Conclusion

The integration of AI with functional multi-omics represents a significant frontier in oncology. By participating in this enlightening session, attendees can familiarize themselves with the latest methodologies and prepare for the evolving demands of drug development in oncology. Don't miss this opportunity to unlock the potential of next-generation data science in the fight against cancer.